ASCiminib with or without dasatinib for chronic myelogenous leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called ASCiminib, possibly combined with dasatinib, for patients with chronic myelogenous leukemia (CML) whose disease didn't respond well to their first treatment. The goal is to see if this combination can control the leukemia better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with chronic phase CML (a blood cancer caused by the BCR::ABL1 gene) and your first treatment didn't work well enough
- Your kidney function is adequate (creatinine clearance ≥30 mL/min)
- Your liver function is adequate (bilirubin, liver enzymes within acceptable limits)
- You have not had a stem cell or bone marrow transplant before
- You are willing to have genetic testing and use effective contraception if you can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests a new drug called asciminib given after a stem cell transplant to prevent the return of a type of leukemia. If you have Philadelphia chromosome-positive B-ALL or blast-phase CML, this may help keep you in remission.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
Hear when a new Chronic Myeloid Leukemia (CML) in trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.